NCT03897257View on ClinicalTrials.gov

A Comparison Study of UHE-103 Cream in Subjects With Moccasin Type Tinea Pedis

PHASE2CompletedINTERVENTIONAL
Enrollment

240

Participants

Timeline

Start Date

March 15, 2019

Primary Completion Date

October 21, 2019

Study Completion Date

May 5, 2020

Conditions
Tinea Pedis
Interventions
DRUG

UHE-103A1 cream

Investigational mono-therapy cream (containing drug A \[low dose\]). Drug A is an antifungal agent.

DRUG

UHE-103A2 cream

Investigational mono-therapy cream (containing drug A \[low dose\]). Drug A is an antifungal agent.

DRUG

UHE-103B cream

Comparator mono-therapy cream (containing drug B). Drug B is a keratolytic agent.

DRUG

UHE-103A1B cream

Investigational combination-therapy cream (containing drug A \[low dose antifungal\] + drug B \[keratolytic\]).

DRUG

UHE-103A2B cream

Investigational combination-therapy cream (containing drug A \[high dose antifungal\] + drug B \[keratolytic\]).

Trial Locations (12)

14623

Site 04, Rochester

23502

Site 05, Norfolk

32935

Site 12, Melbourne

33144

Site 06, Miami

33162

Site 09, North Miami Beach

55432

Site 11, Fridley

60008

Site 07, Rolling Meadows

77055

Site 02, Houston

78229

Site 10, San Antonio

78759

Site 01, Austin

92123

Site 03, San Diego

00739

Site 08, Cidra

All Listed Sponsors
lead

Therapeutics, Inc.

INDUSTRY

NCT03897257 - A Comparison Study of UHE-103 Cream in Subjects With Moccasin Type Tinea Pedis | Biotech Hunter | Biotech Hunter